DefinitionThis section has been translated automatically.
Interleukin-13 (IL-13) is a pleiotropic immunoregulatory cytokine that acts via the IL-13Ra1/IL-4Ra complex. Its functions are similar to those of interleukin-4, and both cytokines share the same receptor. Interleukin-13 has only a weak affinity to its receptor. A high-affinity binding is only achieved by co-expression with the interleukin-4 receptor. Besides the membrane-bound receptor, soluble sIL-13R is also detected.
The gene coding for interleukin-13 is located on chromosome 5 .
General informationThis section has been translated automatically.
Interleukin-13 is formed by activated CD8- and CD4-positive T-lymphocytes. Interleukin (IL)-13 affects numerous cell types such as B cells, monocytes, NK cells, endothelial cells, and fibroblasts. Furthermore, IL-13 inhibits the activation of macrophages.
The cytokine inhibits the release and function of proinflammatory cytokines(Interleukin-1, Interleukin-6, Interleukin-8, Interleukin-10, Interleukin-12, Interleukin-13) as well as TNFalpha. Furthermore, the production of nitric oxide (NO) by macrophages is reduced. In addition, the expression of MHC class II antigens is promoted. The cytokine induces and maintains fibrosing processes and acts as an additive to interleukin-4. Together with interleukin-4, interleukin-13 plays a role in the defence against intestinal nematode infections.
For interleukin-13 and its receptor, overexpressions of interleukin-13 and its receptor (glioblastoma, colorectal carcinoma) have been demonstrated in a number of malignant tumors. From these observations, different treatment regimes were derived.
General therapyThis section has been translated automatically.
Simultaneous blocking of the interleukins (IL)-4 and IL-13 leads to suppression of the clinical symptoms of bronchial asthma and atopic eczema. Dupilumab is a monoclonal antibody directed against the alpha chain of interleukins 13 and -4 inhibits the function of both interleukins. Dupilumab has already proven its efficacy in clinical trials in both bronchial asthma and atopic eczema.
LiteratureThis section has been translated automatically.
- Buzney CD et al(2016) Asthma and Atopic Dermatitis: A Review of Targeted Inhibition of Interleukin-4 and Interleukin-13 As Therapy for Atopic Disease. J Drugs Dermatol 15:165-171.
- Corren J (2013) Role of interleukin-13 in asthma. Curr Allergy Asthma Rep 13:415-420.
- Finkelman FD et al (2004) Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites.Immunol Rev 201:139-155.
- Hess C et al (2015) The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity. Cancer Immunol Immunother 64:635-644.
- Joshi BH et al (2006) Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitamin Horm 74:479-504.
- O'Reilly S (2013) Role of interleukin-13 in fibrosis, particularly systemic sclerosis. Biofactors 39:593-596.
- Rayees S et al (2014) Linking GATA-3 and interleukin-13: implications in asthma. Inflamm Res 63:255-265.
- Kuperman DA et al (2008) Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr Mol Med 8:384-392.
- Seyfizadeh N et al (2015) Interleukin-13 as an important cytokine: A review on its roles in some human diseases. Acta Microbiol Immunol Hung 62:341-378.
- Wills-Karp M (2004) Interleukin-13 in asthma pathogenesis. Immunol Rev 202:175-190.
- Zhou R et al (2013) Interleukin-13 and its receptors in colorectal cancer (Review). Biomed Rep 1:687-690.